Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity-Reference-Cited by-同舟云学术

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity

Published:2019-10-01 Issue:19 Volume:58 Page:2803-2808
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yoshioka Naoki¹,Kuzuya Teiji¹,Ito Takanori¹,Ishizu Yoji¹,Honda Takashi¹,Ishikawa Tetsuya¹,Ishigami Masatoshi¹,Fujishiro Mitsuhiro¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/19/58_2812-19/_pdf

Reference20 articles.

1. 1. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389: 56-66, 2017.

2. 2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.

3. 3. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, Md) 29: 62-67, 1999.

4. 4. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Safety 36: 491-503, 2013.

5. 5. Bunchorntavakul C, Reddy KR. Drug Hepatotoxicity: Newer Agents. Clin Liver Dis 21: 115-134, 2017.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy;Journal of Interventional Medicine;2021-08

2. Regorafenib/sorafenib;Reactions Weekly;2019-12